Biofrontera (NASDAQ:BFRIW – Get Free Report) is anticipated to issue its results before the market opens on Thursday, March 19th. Analysts expect the company to announce earnings of $0.1950 per share and revenue of $16.1460 million for the quarter.
Biofrontera Price Performance
Shares of NASDAQ BFRIW opened at $0.05 on Tuesday. The stock’s 50-day simple moving average is $0.06 and its 200-day simple moving average is $0.08. Biofrontera has a fifty-two week low of $0.03 and a fifty-two week high of $0.28.
About Biofrontera
Biofrontera AG is a biopharmaceutical company headquartered in Leverkusen, Germany, specializing in the development, manufacture and commercialization of dermatology products. Founded in 1997, the company focuses on therapies for skin diseases through innovative drug and device combinations. Its core business centers on photodynamic therapy, where a photosensitizing agent is activated by a specialized light source to treat precancerous and cancerous skin conditions.
The company’s flagship product, Ameluz, is a topical formulation of aminolevulinic acid used in conjunction with the BF-RhodoLED irradiation device.
See Also
- Five stocks we like better than Biofrontera
- The gold chart Wall Street is terrified of…
- Elon Musk already made me a “wealthy man”
- Silver paying 20% dividend. Plus 68% share gains
- Unlocked: Elon Musk’s Next Big IPO
- 1,500 Banks Just Handed the Fed Your Bank Account
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
